Division of Abbott Laboratories Inc.
Latest From eScreen Inc.
The prospective medical device tax, the continuing decline of venture investing, pricing challenges, austerity measures in Europe, and other headwinds continued to push against the medtech industry in 2012. But emerging clinical and geographic markets, along with an active M&A market, are providing the industry with some momentum going into 2013.
Diagnostics industry trends include the increasing adoption of genomics in clinical testing and with it a focus on services and workflow more so than differentiated technology; a slowdown in M&A activity, partly to allow the digestion of assets acquired in 2010-11; and the ongoing uncertainties of regulation and reimbursement of high-value molecular tests.
Medical device companies raised $1.1 billion, a 40% increase over Q4 2011’s $800 million. Two billion-dollar deals in the resuscitation market boosted device acquisition activity to $4.2 billion. Twenty diagnostics financings brought in a collective $302 million, soaring above the previous quarter’s $269 million. There were seven diagnostics M&A deals completed, totaling $589 million – down yet again.
Pfizer and Zhejiang Hisun Pharmaceutical together invested $545 million to create a Chinese generics joint venture. Dainippon Sumitomo Pharma expanded its cancer pipeline though the acquisition of Boston Biomedical. Driven by a large amount of FOPOs, biopharma financing totaled $1.8 billion in February, while device companies raised $248 million.
In Vitro Diagnostics
- Urine-based Testing
- Laboratory Testing Services
- Therapeutic Areas
- North America
- Parent & Subsidiaries
- Abbott Laboratories Inc.
- Laboratory Corp. of America Holdings
- Senior Management
Robert D Thompson, CEO
Thomas J Hespe, Chief Marketing Officer
Roger L Peckman, VP, Fin.
- Contact Info
Phone: (913) 327-5915
7500 W. 110th St.
Overland Park, KS 66210
All set! This article has been sent to email@example.com.
All fields are required. For multiple recipients, separate email addresses with a semicolon.